Jiangsu Recbio Technology Co., Ltd.
SEHK:2179 Rapport sur les actions
Capitalisation boursière : HK$4.2b
Jiangsu Recbio Technology Bilan de santé
Santé financière contrôle des critères 3/6 Jiangsu Recbio Technology possède un total de capitaux propres de CN¥835.8M et une dette totale de CN¥681.3M, ce qui porte son ratio d'endettement à 81.5%. Son actif total et son passif total sont CN¥2.1B et de CN¥1.2B.
Informations clés Ratio de couverture des intérêts n/a Argent liquide CN¥531.30m Fonds propres CN¥835.76m Total du passif CN¥1.22b Total des actifs CN¥2.06b
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
Jiangsu Recbio Technology Co., Ltd. Announces Initiation of Phase Iii Clinical Trial in China of the Company's Novel Adjuvanted Recombinant Shingles Vaccine Rec610 Oct 23
Jiangsu Recbio Technology (HKG:2179) Is Making Moderate Use Of Debt Aug 23
Jiangsu Recbio Technology Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024 Aug 08
Jiangsu Recbio Technology Co., Ltd. Announces Change of Joint Company Secretary Jun 19
Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director May 09
Does Jiangsu Recbio Technology (HKG:2179) Have A Healthy Balance Sheet? Mar 26
Jiangsu Recbio Technology Co., Ltd., Annual General Meeting, May 08, 2024 Mar 21
Jiangsu Recbio Technology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines Dec 29
Consensus revenue estimates increase by 23% Sep 07
New major risk - Financial position Aug 26
Jiangsu Recbio Technology Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress Jul 27
Consensus revenue estimates decrease by 68%, EPS upgraded May 31
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments May 12
Jiangsu Recbio Technology Co., Ltd. Announces Completion of the First Batch of Subject Enrollment for the Phase I Clinical Trial of Novel Adjuvanted Recombinant Shingles Vaccine REC610 Feb 13
Jiangsu Recbio Technology Co., Ltd. Achieves Positive Results for its Sequential Booster Vaccination Phase II Study of the Recombinant Two-Component COVID-19 Vaccine ReCOV in the Philippines Dec 26
Jiangsu Recbio Technology Co., Ltd. Announces That Positive Results Were Achieved for Its Sequential Booster Vaccination Phase Ii Study of the Recombinant Two-Component Covid-19 Vaccine Recov in the Philippines Dec 24
No longer forecast to breakeven Dec 21
Jiangsu Recbio Technology Co., Ltd. Announces Clinical Trial Approval for the Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines Dec 20
Jiangsu Recbio Technology Co., Ltd Announces Positive Results Were Achieved for Its Sequential Booster Vaccination Phase Ii Study of the Recombinant Twocomponent COVID-19 Vaccine Recov in the Philippines Dec 16
Less than half of directors are independent Nov 16
Jiangsu Recbio Technology Co., Ltd. Completes the First Batch of Subject Enrollment for the International Multi-Center Phase Iii Clinical Trial of Recombinant Covid-19 Vaccine Recov Nov 09
Jiangsu Recbio Technology Co., Ltd Announces Update on Overseas Clinical Trials Progress of Novel Adjuvant COVID-19 Vaccine ReCOV Nov 08
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of the Application for Clinical Trial of Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine Oct 28
Jiangsu Recbio Technology Co., Ltd. Announces Completion of Subject Enrollment and Vaccination for the Comparative Study Between Recov and Mrna Vaccines Aug 19
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Gu Zhongcai as Supervisor Aug 17
Jiangsu Recbio Technology Co., Ltd. to Report Q2, 2022 Results on Aug 25, 2022 Aug 13
Jiangsu Recbio Technology Co., Ltd. Provides Phase III Clinical Trial Progress of Recombinant HPV 9-Valent Vaccine Aug 11
Jiangsu Recbio Technology Co., Ltd. Announces Approval of the Comparative Study Between Recov and Mrna Vaccines by Fda in the Philippines Aug 04
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Gu Zhongcai and Wang Hongyang as Supervisor Jul 01
Jiangsu Recbio Technology Co., Ltd. Announces Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines Jun 28 Jiangsu Recbio Technology Co., Ltd. Receives Clinical Trial Approval for its Recombinant Protein COVID-19 Vaccine, ReCOV from National Medical Products Administration of People's Republic of China
Less than half of directors are independent Apr 27
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Xu Yaming as Supervisor Apr 21
Jiangsu Recbio Technology Co., Ltd. Receives Approval from the Ministry of Health and Prevention of the United Arab Emirates For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV Apr 13
Jiangsu Recbio Technology Co., Ltd. has completed an IPO in the amount of HKD 765.1916 million. Mar 31
Less than half of directors are independent Mar 31
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de 2179 ( CN¥795.4M ) dépassent ses passifs à court terme ( CN¥681.6M ).
Passif à long terme: Les actifs à court terme de 2179 ( CN¥795.4M ) dépassent ses passifs à long terme ( CN¥541.3M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de 2179 ( 17.9% ) est considéré comme satisfaisant .
Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de 2179 a diminué au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: 2179 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: 2179 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 19.5 % chaque année
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
